Skip to main content
Clinical Trials/IRCT20181204041847N1
IRCT20181204041847N1
Recruiting
Phase 3

Comparison of the side effects of treatment with Duloxetine plus Electroconvulsive therapy and Sertraline plus Electroconvulsive therapy in patients with treatment resistant major depression

Shiraz University of Medical Sciences0 sites32 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Treatment resistance depression diagnosed by psychiatrist based on DSM5 criteria.
Sponsor
Shiraz University of Medical Sciences
Enrollment
32
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Treatment resistance depression diagnosed by psychiatrist based on DSM5 criteria

Exclusion Criteria

  • Other medical condition
  • Neurological disorder
  • Cardiovascular disease
  • Contraindication to duloxetine and/ or Sertraline
  • Current using other antidepressant(s) or drugs with possible effect on ECT
  • Any contraindication for ECT

Outcomes

Primary Outcomes

Not specified

Similar Trials